Jacobs Levy Equity Management’s Dicerna Pharmaceuticals DRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
– Sell
-62,645
Closed -$1.13M – 1125
2020
Q3
$1.13M Sell
62,645
-10,927
-15% -$226K 0.01% 639
2020
Q2
$1.87M Buy
+73,572
New +$1.58M 0.02% 547
2020
Q1
– Sell
-17,829
Closed -$393K – 1133
2019
Q4
$393K Sell
17,829
-14,100
-44% -$284K ﹤0.01% 817
2019
Q3
$459K Buy
+31,929
New +$456K 0.01% 728
2017
Q1
– Sell
-55,319
Closed -$159K – 1043
2016
Q4
$159K Sell
55,319
-400
-0.7% -$1.42K ﹤0.01% 854
2016
Q3
$328K Sell
55,719
-38,700
-41% -$136K 0.01% 790
2016
Q2
$283K Buy
94,419
+30,473
+48% +$125K 0.01% 896
2016
Q1
$343K Buy
+63,946
New +$404K 0.01% 827

Other funds holding DRNA

Jacobs Levy Equity Management's DRNA Position: Q4 2020 in Review

Jacobs Levy Equity Management sold out of Dicerna Pharmaceuticals (DRNA) in Q4 2020, closing a stake of 62,645 shares — an estimated $1.13M sold.

Jacobs Levy Equity Management first reported a position in DRNA in Q1 2016 and held it in 8 quarters. The position peaked at $1.87M in Q2 2020. 174 funds tracked by Wall St. Rank hold DRNA as of Q4 2020.

  • Jacobs Levy Equity Management reported no remaining Dicerna Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 62,645 Dicerna Pharmaceuticals shares in Q4 2020, an estimated $1.13M.
  • Jacobs Levy Equity Management first reported a position in Dicerna Pharmaceuticals in Q1 2016 and held it in 8 quarters.
  • Jacobs Levy Equity Management's Dicerna Pharmaceuticals position peaked at $1.87M in Q2 2020.
  • 174 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals as of Q4 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2020, filed 16 Feb 2021.